Eli Lilly Acquires Three Vaccine Firms in $3.8 Billion Diversification Play

Eli Lilly has announced the acquisition of three vaccine-focused entities—Curevo, LimmaTech Biologics AG, and Vaccine Company—for a total consideration of $3.8 billion. The transaction is designed to establish a new business unit dedicated to infectious diseases, marking a significant strategic expansion for the pharmaceutical manufacturer.

The move comes as the company seeks to diversify its revenue streams beyond its current dominance in the GLP-1 weight-loss drug market. Mounjaro and Zepbound currently account for nearly two-thirds of Eli Lilly’s top line, generating approximately $12.8 billion in revenue during the first quarter of 2026. Sales for these products surged 125 per cent and 80 per cent year-on-year respectively during that period.

Despite the strong performance of its current portfolio, which also includes the newly released GLP-1 pill Foundayo, the company is acting on the finite nature of pharmaceutical patent protections. Industry analysis indicates that the current revenue windfall from Mounjaro and Zepbound is expected to fade as patents expire, prompting management to leverage today’s financial success to build long-term stability.

The new infectious diseases unit is expected to be inconsequential to the business in the near term. While the acquired companies may not immediately become significant financial winners, the acquisition represents a calculated effort to mitigate the risk associated with the eventual decline of its primary revenue drivers.

Eli Lilly’s current valuation reflects the market’s confidence in its GLP-1 dominance, with a price-to-earnings ratio of approximately 39 times, well above the pharmaceutical industry average of 24 times. This strategic diversification aims to sustain growth momentum as the company navigates the inevitable lifecycle changes within its core drug categories.